These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27390118)

  • 1. The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.
    Chen CH; Yan SL; Yang TH; Chen SF; Yeh YH; Ou JJ; Lin CH; Lee YT; Chen CH
    J Clin Lab Anal; 2017 Jan; 31(1):. PubMed ID: 27390118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
    Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
    World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
    Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
    BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.
    Kalimutho M; Del Vecchio Blanco G; Cretella M; Mannisi E; Sileri P; Formosa A; Pallone F; Federici G; Bernardini S
    Int J Colorectal Dis; 2011 May; 26(5):583-92. PubMed ID: 21225430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Plasma MicroRNA and Fecal Occult Blood Tests in Early Detection of Colorectal Cancer.
    Luo X; Wu Y; Ji M; Zhang S
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma methylated septin 9: a colorectal cancer screening marker.
    Molnár B; Tóth K; Barták BK; Tulassay Z
    Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
    Lohsiriwat V; Thavichaigarn P; Awapittaya B
    J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.
    Su WC; Kao WY; Chang TK; Tsai HL; Huang CW; Chen YC; Li CC; Hsieh YC; Yeh HJ; Chang CC; Wang JY
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33393623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.
    Jin P; Kang Q; Wang X; Yang L; Yu Y; Li N; He YQ; Han X; Hang J; Zhang J; Song L; Han Y; Sheng JQ
    J Gastroenterol Hepatol; 2015 May; 30(5):830-3. PubMed ID: 25471329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the immunofecal occult blood test for colorectal cancer screening in a large population.
    Yang H; Ge Z; Dai J; Li X; Gao Y
    Dig Dis Sci; 2011 Jan; 56(1):203-7. PubMed ID: 20458621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
    Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
    Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
    Church TR; Wandell M; Lofton-Day C; Mongin SJ; Burger M; Payne SR; Castaños-Vélez E; Blumenstein BA; Rösch T; Osborn N; Snover D; Day RW; Ransohoff DF;
    Gut; 2014 Feb; 63(2):317-25. PubMed ID: 23408352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer screening using a stool DNA-based SDC2 methylation test: a multicenter, prospective trial.
    Kim CW; Kim H; Kim HR; Kye BH; Kim HJ; Min BS; Oh TJ; An S; Lee SH
    BMC Gastroenterol; 2021 Apr; 21(1):173. PubMed ID: 33858326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
    Hu J; Hu B; Gui YC; Tan ZB; Xu JW
    Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
    Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA.
    Han YD; Oh TJ; Chung TH; Jang HW; Kim YN; An S; Kim NK
    Clin Epigenetics; 2019 Mar; 11(1):51. PubMed ID: 30876480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.